Healthcare Market Dynamics
Expert articles and analysis related to healthcare market dynamics.
AI Summary — Last 7 Days
VBC activity this week centered on risk-transfer readiness: Arbital Health launched ATLAS to help ACOs model downside exposure under CMS’s LEAD ACO program, while Cedar Gate emphasized episode-model analytics and bundled-payment strategy—signaling a vendor push to operationalize actuarial, episode, and attribution risk as CMS expands accountable-care and specialty-payment models. Rural providers are also organizing for scale, with seven Kansas hospitals forming a clinically integrated network to pursue value-based care capabilities that would be difficult to build independently. Meanwhile, Medicare Advantage remains a volatile benchmark environment: the Trump administration finalized a 2.48% MA payment increase for 2026, while CMS’s recalculation of certain MA Star Ratings following litigation could shift quality-bonus economics for plans such as Humana and Clover, reinforcing the need for ACOs, CINs, and payer partners to stress-test revenue assumptions against policy and methodology changes ([ATLAS/LEAD ACO risk modeling](https://news.google.com/rss/articles/CBMixwFBVV95cUxNTVg3ekJxUXl5VndEbjhXVmR6WUo4UGoyWHROTTVmUmF4LXdOOTBjNno4Sll3MjhVYm1CSm9wbVhGUWxJWEphUDF0emlnbGdrUmcwWXFzOVZhRnFETE0wY2VKbk1JNE5XaU5
Related Articles
Rural, independent Kansas hospitals launch clinically integrated network
Rural, independent Kansas hospitals launch clinically integrated network Fierce Healthcare
7 rural Kansas hospitals form clinically integrated network
7 rural Kansas hospitals form clinically integrated network Becker's Hospital Review
CMS Could Make Drug Price Negotiations Permanent
CMS Could Make Drug Price Negotiations Permanent - What it Means for Pharma Pharmaceutical Commerce
The 340B Drug Pricing Program at a Crossroads
The 340B Drug Pricing Program at a Crossroads JAMA
Colorado wins FDA approval to import prescription drugs from Canada
Colorado wins FDA approval to import prescription drugs from Canada Becker's Hospital Review
The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs
By Bryce Platt, PharmD For years, Medicare Part D plans often preferred high-list/high-rebate branded multiple sclerosis (MS) drugs over lower-cost generics. That was rational behavior inside an irra...
PCMA sues to exempt PBMs from Illinois drug law
The drug middlemen lobby has had a busy week. It’s the second major lawsuit the PCMA has filed against a state law reforming the PBM industry since Monday.
STAT+: Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims data
Making good on its threat, Eli Lilly has begun eliminating mandated price breaks to a few dozen hospitals that participate in a federal drug discount program.
Why Pharma Cost Trend Is Outpacing Overall Medical Trend
Why Pharma Cost Trend Is Outpacing Overall Medical Trend Pharmaceutical Commerce
Lilly halts 340B drug discounts, triggers fury
Lilly halts 340B drug discounts, triggers fury Modern Healthcare News